BILL ANALYSIS

HR3482

NEUTRAL

Veterans Community Care Scheduling Improvement Act

HR3482 (Veterans Community Care Scheduling Improvement Act) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

3/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

HR3482 is a procedural scheduling mandate, not a funding or volume bill.

No dollar amount is authorized or appropriated — any eventual spending is speculative.

Healthcare tickers ($DGX, $LH, $HCA, $UHS, $AMN) show no price reaction to this legislative action.

The bill is in early relative stage (House calendar, no Senate action) — passage is uncertain.

Real impact on community care providers requires future appropriations; current data shows zero economic effect.

How HR3482 Affects the Market

No direct market implications for retail investors at this stage. The 30-day price trends for $DGX (-0.37%), $LH (-1.08%), $HCA (-9.45%), $UHS (-5.65%), and $AMN (+10.8%) are driven by other factors (earnings, sector rotations, reimbursement concerns) — not this bill. Watch for appropriations riders in future VA funding bills; without those, this legislation is administrative housekeeping.

Bill Details

Metric	Value
Bill Number	HR3482
Market Sentiment	neutral
Event Date	March 30, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

HR3482 is a procedural authorization bill requiring the VA to build an online scheduling system for community care appointments. It mandates an IT system change but includes no explicit funding, and it does not directly increase patient volume or reimbursement rates. The market impact on healthcare stocks ($DGX, $LH, $HCA, $UHS, $AMN) is negligible in the near term.

Full AI Market Analysis

1) What happened and its current status: HR3482, the Veterans Community Care Scheduling Improvement Act, was introduced on May 19, 2025, by Rep. Tom Barrett (R-MI-7). It cleared the House Committee on Veterans Affairs and was reported out amended on March 30, 2026. It is now on the Union Calendar (Calendar No. 496), awaiting floor consideration. The bill has active legislative momentum with 11 recorded actions, but is not yet law. 2) The money trail — authorization vs. appropriation: The bill sets a policy mandate for the VA to create an online IT scheduling system but does NOT authorize or appropriate any specific dollar amount. Without an appropriations rider, funding would have to come from the VA's existing administrative budget or future appropriations. The scale of eventual spending is unknowable from the bill text. No guarantees of incremental patient volume to community providers exist — the bill does not change eligibility, reimbursement, or network requirements. 3) Structural winners and losers: The bill does not directly create revenue for any listed ticker. The VA already contracts with community providers; this bill only changes how appointments are scheduled internally. Without volume or reimbursement changes, diagnostic labs ($DGX, $LH), hospital chains ($HCA, $UHS), and staffing firms ($AMN) see no direct revenue catalyst. Any benefit to private providers is indirect, speculative, and requires multiple appropriations steps still ahead. 4) Real market data analysis: Over the past 30 days, $DGX is down 0.37%, $LH down 1.08%, $HCA down 9.45%, $UHS down 5.65%, and $AMN up 10.8%. None of these moves correlate with the bill's legislative timeline — movements appear driven by broader sector trends (hospital stocks have sold off sharply since late April). On April 30, 2026, the same day the bill calendar was updated, $DGX closed at $195.26, $LH at $263.92, $HCA at $428.50, $UHS at $168.86, and $AMN at $20.32. No price spikes on this news. 5) Timeline: The bill must pass the full House, then the Senate (no companion bill exists), be reconciled if amended, and then be signed. Even if enacted, the VA has one year to build the system. Actual patient volume changes would require separate appropriations bills. Near-term (next 6 months) market impact: none.